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Abstract: Obstructive sleep apnea (OSA) is independently associated with cardiovascular and
cardiometabolic risk in several large epidemiologic studies. OSA leads to several physiologic
disturbances such as intermittent hypoxia, sleep fragmentation, and increase in autonomic tone.
These disturbances have been associated with insulin resistance and type 2 diabetes mellitus
(T2DM) in animal and human studies. Studies also suggest a bidirectional relationship between
OSA and T2DM whereby T2DM itself might contribute to the features of OSA. Moreover,
successful treatment of OSA may reduce these risks, although this is controversial. The purpose
of this article is to review 1) the links and bidirectional associations between OSA and T2DM;
2) the pathogenic mechanisms that might link these two disease states; 3) the role of continuous
positive airway pressure therapy in improving glucose tolerance, sensitivity, and resistance;
and 4) the implications for clinical practice.
Keywords: Insulin resistance, metabolic syndrome, sleep disordered breathing, intermittent
hypoxia

Introduction
Obstructive sleep apnea (OSA) is a growing medical problem, with moderate-to-severe
cases affecting 10%–17% of men and 3%–9% of women between the ages of 30 years
and 70 years.1 OSA is characterized by repeated upper airway occlusions during sleep
that result in specific physiologic perturbations, including sleep fragmentation and
chronic intermittent hypoxia (CIH). These disturbances can lead to a cascade of events
related to the activation of the sympathoadrenal system, oxidative stress, systemic
inflammation, and changes in adipokines – all of which can be important in increasing the
risk of cardiovascular disease, hypertension, metabolic syndrome, and diabetes.2–4 The
present review will focus on the associations and pathophysiologic mechanisms that link
OSA with the development of type 2 diabetes mellitus (T2DM).

Epidemiological links between OSA and T2DM
Prevalence of T2DM in patients with OSA
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Several large-scale, cross-sectional, and epidemiological studies have suggested that
OSA is an independent risk factor for the development of T2DM, and that as many
as 15%–30% of patients with OSA have this comorbidity.5 Moreover, as the severity
of OSA increases, so does the likelihood T2DM incidence and of worse glycemic
control in patients with T2DM.6
The Sleep Health Heart Study (SHHS) was a large, prospective cohort study designed
to investigate the role of OSA as a risk factor for the development of cardiovascular
113

submit your manuscript | www.dovepress.com

Nature and Science of Sleep 2015:7 113–125

Dovepress

© 2015 Rajan and Greenberg. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on
how to request permission may be found at: http://www.dovepress.com/permissions.php

http://dx.doi.org/10.2147/NSS.S90835

Rajan and Greenberg

and other chronic diseases.7 This study provided evidence of
an independent association between OSA severity and both
impaired glucose tolerance and insulin resistance. OSA severity was measured by the apnea–hypopnea index (AHI), which
reflects the number of apneas/hypopneas per hour of sleep and
whereby AHI ,5/h is considered normal, AHI 5–15/h is mild,
AHI 15–29/h is moderate, and AHI .30/h is severe. Impaired
glucose tolerance was defined as a fasting plasma glucose level
of 110–125 mg/dL and a 2-hour oral glucose tolerance test
(OGTT) between 140 mg/dL and 200 mg/dL. After adjustment for multiple potential confounders, including age, body
mass index (BMI), waist circumference, and self-reported
sleep duration, subjects with mild- or moderate-to-severe
OSA had odds ratios (ORs) of 1.27 (95% confidence interval
[CI] 0.98–1.64) and 1.46 (95% CI 1.09–1.97), respectively,
for impaired glucose tolerance compared with subjects with
normal AHIs. The severity of nocturnal hypoxemia was also
independently associated with glucose intolerance. In addition, OSA severity was associated with increased insulin
resistance, which was measured by the homeostasis model
assessment insulin resistance (HOMA-IR) index.7
The Wisconsin Sleep Cohort was another large, prospective study that found a significant correlation between the
severity of OSA and the prevalence of diabetes: 2.8% of
subjects with an AHI of ,5/h had the diagnosis of diabetes,
compared to 14.7% of subjects with an AHI of $15/h. The
OR for the diagnosis of diabetes was 2.30 (95% CI 1.28–4.11;
P=0.005) in subjects with an AHI of $15/h, compared with
subjects with an AHI of ,5/h, after adjustment for age, sex,
and body habitus. On the other hand, a 4-year longitudinal
analysis of 978 participants without diabetes at entry did not
demonstrate a statistically significant association of diabetes
incidence with severity of OSA at baseline, after adjustment
for potential confounders at the end of the 4-year period.8
The findings of the Busselton Health Study also noted
an association between OSA and higher T2DM prevalence
over a 4-year follow-up period. After adjustment for age,
sex, BMI, waist circumference, HDL cholesterol, and mean
arterial pressure, moderate-to-severe OSA was found to be
an independent risk factor for 4-year incident diabetes (OR
13.45, 95% CI 1.59–114.11) and a univariate risk factor for
prevalent diabetes (OR 4.37, 95% CI 1.12–17.12).9

Prevalence of OSA in subjects
with T2DM
The studies described previously demonstrated independent
associations of OSA with insulin resistance and T2DM.
Conversely, studies assessing the prevalence of OSA in
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patients with existing T2DM have found remarkably high
rates of OSA.5,10,11 These findings have raised the possibility of T2DM as a risk factor for the development of OSA
in a bidirectional fashion. The prevalence of OSA in obese
subjects with T2DM was assessed with ambulatory nocturnal
respiratory monitoring in The Sleep Action for Health in
Diabetes (AHEAD) study, a four-site ancillary study of the
Look AHEAD Trial. This is a 16-center trial investigating
the long-term health impact of lifestyle intervention designed
to achieve and maintain weight loss in over 5,000 obese
adults with type 2 diabetes. Sleep testing was performed in
306 participants in the Sleep AHEAD study; surprisingly,
86.6% of obese subjects with type 2 diabetes in this study had
an AHI indicative of sleep apnea (AHI $5/h). The mean AHI
in this cohort was in the moderate range at 20.5±16.8/h. Of
these patients, 30.5% had moderate OSA (AHI 15–29/h) and
22.6% had severe OSA (AHI $30/h). Severe OSA was most
likely as BMI increased (OR 1.1; 95% CI 1.0–1.2; P=0.03).10
These findings could be secondary to the common risk factor
for obesity but also raise the possibility that T2DM might
contribute to OSA, as will be discussed in future sections.

Association of OSA with metabolic
syndrome
OSA is closely associated with metabolic syndrome because
of shared risk factors. The term “Syndrome Z” has been
developed to describe the links between obesity, insulin resistance, hypertension, and dyslipidemia with OSA. The OR for
the presence of metabolic syndrome in patients with OSA
ranges from fivefold to as high as ninefold, when compared
to subjects without OSA, independent of age and BMI.12–14
In a Chinese population-based study of 255 subjects, severity of OSA correlated with an increasing prevalence of the
metabolic syndrome.14 A Japanese case-control study analyzed lean men of normal BMI with and without OSA and
demonstrated an association of OSA with the following three
components of the metabolic syndrome: insulin resistance,
hypertension, and dyslipidemia.15 Although it is difficult to
exclude obesity as major contributing factor for the association of OSA with metabolic syndrome, these studies provide
evidence that factors other than obesity may mediate this
relationship. Some of these potential mediators are discussed
in the following sections.

Associations of OSA with nonalcoholic
fatty liver disease and insulin resistance
Another clinical condition that is closely linked with the
metabolic syndrome is nonalcoholic fatty liver disease
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(NAFLD), a common liver disease characterized by excessive fatty deposits in the liver. NAFLD is closely related
to insulin resistance and has also been recently associated
with OSA. The CIH induced by OSA can result in structural
damage to the liver with subsequent hepatic fibrosis and
inflammation.16–19 These changes appear to be independent of
obesity since they are seen among both obese and nonobese
patients with OSA.18 Moreover, there is an independent
association between the severity of the nocturnal hypoxemia
and steatosis that is exacerbated by preexisting obesity. These
results were subsequently confirmed in pediatric patients
with OSA.20

Potential pathogenic mechanisms
linking OSA to insulin resistance
and T2DM

OSA can lead to insulin resistance and pancreatic β-cell
dysfunction through many intermediary pathways. The
upper airway occlusion during sleep that is characteristic
of OSA can be partial, resulting in hypopneas, or complete,
resulting in apneas. These disordered breathing events result
in several pathophysiological perturbations, including sleep
fragmentation, activation of the autonomic system, and
CIH21,22 (see Figure 1).

Sleep fragmentation
Sleep fragmentation in the face of normal sleep duration is
a common consequence of OSA and results from frequent
arousals that often occur at the termination of sleep-disordered
breathing events. These are detected on the cortical electroencephalogram and can contribute to elevated sympathetic
activity and the symptom of daytime somnolence, which is a
characteristic clinical feature of OSA.23 Sleep deprivation and
fragmentation are likely risk factors for obesity via effects on
metabolism and inflammation. Sleep fragmentation associated with OSA most likely also plays an important role in the
development of insulin resistance in many of these patients.
Exposing human subjects to acute sleep fragmentation was
shown to decrease insulin sensitivity.24,25 A recent animal
study also found decreases in visceral and adipose cell insulin sensitivity in mice that were exposed to sleep disruption
during their natural sleep period. Importantly, this study
also provided a potential mechanistic link between sleep
fragmentation and insulin resistance. It posited that sleep
fragmentation reduced insulin sensitivity through observed
increases in macrophage number and infiltration in visceral
fat along with increases in Nox2 (nicotinamide adenine
dinucleotide phosphate oxidase) activity, both of which are
markers of increased oxidative stress.26

Obstructive sleep apnea

Intermittent hypoxia

Sympathetic nervous
system activation

Sleep fragmentation

Oxidative stress
HPA axis alterations
inflammatory pathways
adipokine changes

Insulin resistance
pancreatic β-cell dysfunction

T2DM + prediabetes
Figure 1 Links between obstructive sleep apnea and the development of glucose intolerance and T2DM.
Abbreviations: HPA, hypothalamic–pituitary–adrenal axis; T2DM, type 2 diabetes mellitus.
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Autonomic nervous system activation
Activation of the autonomic nervous system occurs in
association with obstructive apneas and hypopneas; parasympathetic activity tends to predominate during apneas;
and sympathetic tone increases at the termination of apneic
events. Sympathetic neural drive may be increased at the
termination of disordered breathing events as a result of
hypoxia-related activation of peripheral chemoreceptors
as well as from the effects of sudden arousal from sleep.
In addition, elevated levels of circulating and urinary catecholamines have been observed in OSA. Interestingly,
elevated sympathetic tone not only is evident during sleep
but also seems to persist during the day, even when breathing
is normal in patients with OSA.27,28

Intermittent hypoxia
Another very important pathophysiological feature of OSA
relates to episodes of intermittent hypoxia and reoxygenation,
which are associated with disordered breathing events. These
periods of oxyhemoglobin desaturation and resaturation can
lead to intermittent tissue hypoxia followed by reoxygenation,
which has physiologic consequences that differ from those
of chronic hypoxia. The repetitive decreases and increases
in oxygen saturation contribute to the formation of reactive
oxygen and nitrogen species that increase oxidative stress
and can activate redox-sensitive cellular signaling pathways
important in inflammation.29–33
To assess the impact of chronic exposure of intermittent
hypoxia on various physiological parameters, many small
animal models have been developed. Most of these protocols
entailed placing rodents in chambers during their sleep periods
that are flushed with room air (fraction of inspired oxygen
[FIO2] 0.21) followed by different gas mixtures with FIO2
typically at 5% or less with varying cycle times. The resultant
hypoxemia may be analogous to that which occurs in severe
human OSA. However, this model has been criticized because
the extreme reductions in FIO2 might lead to hypoxemia that
is more severe than that seen in mild-to-moderate OSA in
humans.34 Further, the model is also typically associated with
hypocapnia, which might not be apparent in OSA in a clinical
situation. Nevertheless, this model has provided important
insights, regarding the impact of one of the main pathophysiological features of OSA, namely CIH. CIH in the animal
model has been shown to activate the proinflammatory transcription factor nuclear factor-κβ (NF-κβ) in cardiovascular
tissues.35 Activation of NF-κβ has also been demonstrated in
circulating leukocytes in patients with OSA and is reversible
with the treatment of OSA.31
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In summary, sleep fragmentation, changes in autonomic
tone, and CIH all have the combined effects of increasing
sympathetic activation, causing alterations in the HPA axis,
increasing oxidative stress, and activating inflammatory
pathways. These in turn can result in insulin resistance
and pancreatic β-cell dysfunction.21 The impact of CIH on
overall insulin sensitivity, sympathetic neural activation, and
organ-specific tissues will be discussed in the subsequent
sections.

CIH decreases overall insulin sensitivity
Many studies have suggested a link between impaired insulin
sensitivity and intermittent hypoxemia, which is an important
component of OSA. Both animal and human data indicate that
CIH can impair glucose tolerance and clearance and can also
increase the HOMA index, a marker of insulin resistance.36
In order to mimic the CIH associated with severe OSA,
an animal study used a model of CIH in mice with exposure
to CIH during their sleep period, with a return to room air
conditions for the remainder of the day. Exposure protocols
ranged from hours to several months. The hyperinsulinemic–
euglycemic clamp technique was then used to assess insulin
sensitivity during exposure to CIH. The CIH group had a
21% reduction in the amount of exogenous glucose necessary to maintain euglycemia during the hyperinsulinemic–
euglycemic clamp, indicating that CIH induced insulin
resistance in these mice. They also exhibited elevated fasting
glucose, providing strong evidence for a causal relationship
between exposure to CIH and insulin resistance, independent
of obesity. Similar findings were also observed in mice with
diet-induced obesity and genetic obesity.16,36
Human data have subsequently confirmed these findings.
Exposing healthy human volunteers to a hypoxic alternating
with normoxic gas mixture (to mimic the CIH often seen with
patients with moderate sleep apnea) resulted in decreased
insulin sensitivity without a commensurate increase in
insulin secretion, indicative of insulin resistance. This study
also noted a decrease in “glucose effectiveness”: the ability
of glucose to stimulate its uptake by peripheral tissues and
to suppress hepatic glucose production independent of an
insulin response.37

CIH causes sympathetic activation
A potential mechanism linking CIH with peripheral insulin
resistance is the increased sympathetic neural activity with
elevation in catecholamines that occurs with exposure to
CIH.28 These catecholamines both decrease peripheral insulin-mediated glucose uptake and increase insulin resistance.38
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In addition, activation of the hypothalamic–pituitary–adrenal
axis impairs insulin sensitivity and also increases mobilization of glucose. Animal studies have also assessed the impact
of CIH-induced sympathetic nervous system activation on
insulin resistance using a ganglionic blocker (hexamethonium) to prevent autonomic activation. However, blockade
of autonomic activity had no impact on the development of
insulin resistance in response to CIH. Therefore, mechanisms
other than sympathetic neural activation seem to be responsible for the development of insulin resistance, at least in
animal models of CIH. Nevertheless, in a clinical setting,
overactivation of the sympathetic nervous system, as well
as the hypothalamic–pituitary–adrenal axis, occurring as a
result of sleep apnea and its associated sleep fragmentation,
might contribute to insulin resistance in OSA along with
other factors.

The effects of CIH on organspecific tissue
CIH and the pancreas
Insulin resistance is an important factor in the pathophysiology
and evolution of diabetes. However, clinical diabetes develops
when pancreatic β-cells are unable to compensate for increasing insulin resistance. β-cell dysfunction may lead to impairment of the compensatory increases in insulin secretion that
are required to maintain normal levels of blood glucose in the
setting of progressive insulin resistance. Recent data have suggested various mechanisms for pancreatic β-cell dysfunction.
Lean mice exposed to CIH during their sleep period had
elevated plasma fasting insulin levels without a change in
glucose, suggesting the presence of insulin resistance. Despite
this, there was no compensatory pancreatic β-cell proliferation
or hypertrophy in these animals. Rather, insulin content was
decreased in the pancreatic islets due to downregulation of the
enzyme prohormone convertase 1 that converts proinsulin to
insulin. Furthermore, the animals exposed to CIH had impaired
insulin secretion with impairment of insulin synthesis and
processing in the pancreatic β-cells.39 CIH can also result in
β-cell apoptosis, through the interaction between apoptosisrelated proteins (Bcl-2 and Bax). CIH-mediated oxidative
stress results in a downregulation of Bcl-2 and upregulation
of Bax, and this imbalance promotes apoptosis.40
Additional animal studies have also suggested a possible
role for mitochondrial-derived ROS in CIH-induced pancreatic β-cell injury and dysfunction.39 Finally, cellular studies
in vitro have demonstrated CIH-induced downregulation of
CD38 gene expression, which is an important gene involved
in insulin secretion through the mobilization of Ca2+.41
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Impact of CIH on the liver
In both animal and human studies, CIH has been shown to
induce structural liver damage and increase liver enzyme
levels such as serum alanine aminotransferase, aspartate
aminotransferase, and alkaline phosphatase.18,19 In animal
studies, several weeks of CIH exposure resulted in liver steatosis, necrosis, and inflammation with resultant neutrophil
accumulation and collagen deposits. The mechanisms may
involve increased synthesis of lipid biosynthesis enzymes,
proinflammatory cytokines, and oxidative processes, resulting in DNA damage and apoptosis.17–19
A study showed that after 5 weeks of CIH, both hypoxiainducible factor 1α (HIF-1α) and NF-κβ transcription factors were upregulated in the liver.42 CIH exposure results in
increased lipid biosynthesis enzymes in the liver, such as
sterol regulatory element–binding protein-1 (SREBP-1),
sterol-coenzyme A desaturase-1 (SCD-1), and high-density
lipoprotein (HDL) receptor,43 and thus plays an important
role in the development of NAFLD and the metabolic syndrome. CIH also increases the expression of proinflammatory cytokines such as tumor necrosis factor-α (TNF-α) and
macrophage inflammatory protein 2 in obese mice exposed
to 4 weeks of CIH. Interestingly, there was no observed
increase in these cytokines among lean mice.16 Another study
observed increased liver proinflammatory cytokines such
as interleukin (IL) 1β, IL-6, and macrophage inflammatory
protein 2 in lean mice exposed to longer periods of CIH.18
CIH also results in upregulation of nitric oxide metabolites
and reduced activity of liver antioxidant enzymes, which can
contribute to DNA damage and apoptosis.42 In addition, CIH
can not only increase glucose output from hepatocytes but
also upregulate gene expression and protein levels of several
gluconeogenic enzymes in the liver,44 which can contribute
to fasting hyperglycemia and development of T2DM.

CIH and skeletal muscle
Skeletal muscle is responsible for the majority of insulininduced glucose uptake. Despite this, few studies have
examined the effect of CIH on skeletal muscle metabolism
and glucose uptake. A study using a mouse model of CIH
observed not only decreases in whole-body insulin sensitivity
but also reduces glucose utilization and insulin sensitivity
in the soleus muscle, suggesting a clear decrease in glucose
metabolism and uptake in this muscle. The impact of CIH was
most pronounced in oxidative muscle fibers, while glycolytic
muscle fibers were relatively unaffected. Thus, glucose uptake
in oxidative muscle tissue is impaired by CIH and this effect
appears independent of obesity.45
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CIH and adipose tissue
There have been many recent advances in our understanding
of the role of white adipose tissue (WAT) in normal physiological function and in response to endogenous stressors.46–48
WAT not only serves as a reservoir of stored energy in the
form of triacylglycerols but also serves as an important endocrine organ involved in a variety of metabolic activities. It is
especially important for its role in insulin resistance through
the release of free fatty acids (FFAs) during lipolysis.49
These induce insulin resistance through their effects on liver,
muscle, and adipose tissue itself. CIH can cause dyslipidemia
through an increased FFA release; interestingly, this effect
is normalized by oxygen supplementation in humans.50 CIH
can cause decreased lipoprotein clearance through HIF-1 and
angiopeoitin-like 4 inhibition of lipoprotein lipase.51 CIH
also downregulates the potent insulin-sensitizing hormone
adiponectin in T3-L1 adipocytes. This increases adipose
tissue production of resistin, which contributes to further
insulin resistance through inflammatory pathways involving
cytokines such as TNF-α and IL-6.52
There is also increasing evidence that regions with
enlarged areas of visceral adipose tissue experience
hypoxia53,54 as a result of reduced adipose tissue blood
flow. This occurs as adipocytes hypertrophy and their size
exceeds the diffusion capacity of oxygen, thus reducing
regional perfusion of adipose tissue.49 This hypoxic stress
also activates inflammatory signaling pathways, including
HIF-1α and NF-κβ.53 OSA in this population can exacerbate tissue hypoxia and further contribute to adipose tissue
inflammation, providing an additional pathway leading to
insulin resistance and cardiometabolic morbidity. Adipose
tissue hypoxia also leads to the expression and release of
various “adipokines”, which are hormones and cytokines that
have important functions in health and disease. Proinflammatory adipokines (including cytokines, chemokines, and
acute-phase proteins such as haptoglobin and plasminogen
activator inhibitor 1) play particularly important roles in the
development of obesity-related insulin resistance. These substances are associated with obesity-induced proinflammatory
states and they are elevated in the circulation of obese subjects with insulin resistance, whereas the antiinflammatory
adipokine, adiponectin, is diminished in the circulation of
these subjects. As adipocytes increase in size, macrophages
are attracted to and retained within adipose tissue through
the actions of chemokines, MCP-1, and MIF, respectively.
Consequently, infiltration of type M1-macrophages occurs,
and these in turn secrete the proinflammatory cytokines IL-6
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and TNF-α. Hence, the M1-macrophage arrival in adipose
tissues increases the degree of inflammation in already
inflamed tissues. Such inflammatory processes play a significant role in the development of insulin resistance through
inhibition of adipocyte storage of lipids, secretions of adipokines, enhanced lipolysis, and reduced reesterification of
FFAs resulting in elevation in FFAs in the circulation.

Potential pathogenic mechanisms
linking T2DM to OSA
As mentioned previously, there is a higher prevalence of
OSA in patients with T2DM than in nondiabetic patients.
This has led to the question of whether a reverse causality
exists, whereby diabetes itself might lead to some of the
features of OSA. Potential mechanisms for the association of
OSA among diabetic populations include altered ventilatory
control and increased oxidative stress.55,56
Some studies have shown that insulin resistance is associated with a reduced hypercapnic and hypoxic ventilatory
response that is reversed with insulin treatment.57 However,
it is unclear whether this reduced ventilatory response can
exacerbate apneas and hypopneas. Yet other studies have
found an association between diabetes and increased risk of
central sleep apnea, possibly mediated by autonomic dysfunction that can in turn cause increased central chemoreceptor
responsiveness to hypercapnia, thereby predisposing patients
to periodic breathing and central sleep apnea.11,58–60 Indeed,
diabetic patients with autonomic neuropathy have a higher
prevalence of OSA, more severe OSA, longer duration of
sleep disordered breathing events, and more severe oxygen
desaturations when compared with diabetic patients without
autonomic neuropathy.59
Chronic hyperglycemia can also contribute to the development of OSA by increasing oxidative stress. This in turn
can result in structural nerve damage and dysfunction with
worsening autonomic dysfunction.59
In summary, various possible pathogenic mechanisms
might contribute to the association of OSA among diabetic
populations, suggesting that there is a bidirectional relationship between OSA and T2DM.

Continuous positive airway pressure
therapy in OSA improves glucose
control
Continuous positive airway pressure (CPAP) is the goldstandard treatment of OSA and is highly effective in relieving
the symptoms of OSA. However, its impact on comorbidities,

Nature and Science of Sleep 2015:7

Dovepress

such as diabetes, is less clear with studies demonstrating
variable effects on markers of insulin resistance and insulin
sensitivity. A recent meta-analysis of randomized controlled
studies examining the effects of CPAP on measures of glycemic control suggested that while CPAP does not decrease
hemoglobin A1c (HbA1c) level or BMI in patients who have
OSA and T2DM, it may improve insulin sensitivity.61 The
variable results may be related to differences in methods of
assessment of insulin sensitivity, variation in study population
characteristics, and inconsistent adherence to and duration
of CPAP therapy. Nevertheless, there are data to suggest that
use of CPAP can increase insulin sensitivity and decrease
insulin resistance.

CPAP in OSA might improve
insulin sensitivity
Several studies have suggested that CPAP improves
insulin sensitivity. An observational study demonstrated
significant improvement in sensitivity (measured by the
hyperinsulinemic–euglycemic clamp technique) after 2 days
and 3 months of CPAP therapy in patients with moderate-tosevere OSA. Interestingly, this improvement was most pronounced in the subgroup of subjects with a BMI ,30 kg/m2.62
A meta-analysis of 12 prospective observational studies
of nondiabetic adults who were newly diagnosed with
moderate-to-severe OSA demonstrated that CPAP treatment
for 3–24 weeks resulted in a significant decrease in insulin
resistance as assessed by HOMA-IR.63
Several other randomized controlled trials have also
shown significant improvements in insulin sensitivity in
patients with OSA who are treated with CPAP, compared
with sham-CPAP. In these studies, insulin sensitivity was
assessed by the Gutt index, the quantitative insulin sensitivity check index, the short insulin tolerance test, and the
hyperinsulinemic–euglycemic clamp technique.64–66 One
such study showed a trend toward improvement in insulin
sensitivity after CPAP therapy using the hyperinsulinemic–
euglycemic clamp; however, the degree of improvement
did not reach statistical significance.67 It is possible that the
failure to obtain a statistically significant result was because
mean nightly usage of CPAP in that study was only 3.6 hours.
In another study, nightly CPAP therapy for OSA resulted in a
significant increase in Kitt (glucose disappearance rate) in as
little as 1 week of nightly use.65 A review and meta-analysis
by Feng et al obtained information from prospective studies
examining the effects of CPAP on markers of diabetes in
patients with OSA and T2DM. Their findings indicate that
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CPAP does not improve BMI or glycemic control (measured
by HbA1c level) but confirm that it may improve insulin
sensitivity in patients with OSA and T2DM, as assessed by
the hyperinsulinemic–euglycemic clamp method.61
The differing methodologies utilized to assess insulin
sensitivity, patient characteristics, and CPAP adherence rates
in prior studies may explain some of the variability in their
results. For example, the quantitative insulin sensitivity check
index test has a substantially better linear correlation with
hyperinsulinemic–euglycemic clamp than HOMA-IR and
performs better in patients with insulin resistance. Likewise,
HOMA-IR is a good surrogate for the effect of insulin on
hepatic gluconeogenesis but may not accurately measure
other facets of insulin response and may be less accurate,
particularly in the setting of severely impaired pancreatic
β-cell function.68 Furthermore, OSA, and CPAP treatment
itself, may alter and interact with various aspects of insulin
and glucose metabolism such as skeletal muscle insulin
sensitivity and pancreatic β-cell function that may not be
adequately assessed by the metrics used in these studies.65
Importantly, a common limitation in most of these trials
was the limited hours of CPAP use. On average, CPAP use
ranged from 3.3 hours/night to 6.2 hours/night. In order
to evaluate the role of increasing hours of usage of CPAP,
another randomized placebo-controlled study demonstrated
incremental improvement in the insulin sensitivity index
with each additional hour of nightly CPAP use. However,
in this study, significant improvements in insulin sensitivity were observed only in patients with severe OSA
(AHI .30/h).66 In order to further assess the impact of
increased hours of usage, a recent control study randomized patients either to receive CPAP 8 hours nightly or to
receive an oral placebo. Adherence to CPAP was monitored
with continuous supervision in a sleep laboratory. Glucose
metabolism was measured with the 2-hour OGTT. In the
8-hour/night CPAP group, glucose levels were reduced
and insulin sensitivity was increased when compared to
placebo. In addition, circulating norepinephrine levels and
24-hour blood pressure were also reduced in the CPAP
group as compared to placebo.69 This study highlighted the
importance of adherence to CPAP therapy when assessing
its impact on these parameters.

CPAP in OSA improves HbA1c
The percentage of HbA1c, a marker of long-term glucose
control in diabetic individuals, has been shown to be positively correlated with the severity of OSA in patients with
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T2DM. HbA1c increases with the severity of OSA after
adjusting for age, sex, BMI, race, number of antidiabetes medications, exercise, duration of diabetes, and total
sleep time compared to patients without OSA.70 A number
of studies have shown an improvement in HbA1c after
3 months of CPAP therapy.71–73 A recent meta-analysis by
Gallegos et al demonstrated significant improvement in
HbA1c levels and/or increase in insulin sensitivity with
.3 months of CPAP therapy among patients who had OSA
and either prediabetes or T2DM as determined by laboratory evaluation.74
Predictably, the magnitude of improvement in HbA1c
was strongly correlated with the number of hours of nightly
usage of CPAP.71 In one study, patients who utilized CPAP
for .4 hours/night (mean 6.6 hours/night) achieved the greatest improvement in HbA1c.71 In contrast, another investigation where the mean duration of nightly CPAP use was only
3.6±2.8 hours/night noted no significant improvements in
HbA1c or BMI. However, there was significant improvement
in insulin sensitivity.67
These findings indicate that long-term CPAP therapy
for OSA may produce significant improvements in glucose
metabolism and control in T2DM and even prediabetes, but
adequate nightly adherence to CPAP is essential to achieve
this outcome.

Impact of therapy for OSA
on metabolic syndrome
As discussed in a previous section, OSA might be an independent risk factor for the development of metabolic syndrome.75
Elevated systemic arterial hypertension, hyperglycemia,
hypertriglyceridemia, hypercholesterolemia, abdominal and
visceral obesity, and insulin resistance are all components of
metabolic syndrome and have the potential to significantly
increase the risk of diabetes, cardiovascular, and cerebrovascular disease.75
Several studies have explored the effect of CPAP
therapy for OSA on metabolic syndrome and its specific
components.64,76,77 The greatest impact of CPAP therapy
appears to be on systemic arterial pressure. Several randomized placebo controlled studies have demonstrated significant
reductions in arterial blood pressure with CPAP therapy for
OSA.65,76,78 One such study even showed that systemic arterial pressure significantly increased upon CPAP withdrawal
among patients with OSA who were previously treated with
CPAP, providing further evidence for the impact of CPAP
therapy on hypertension in OSA.78
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Hyperlipidemia is another component of metabolic syndrome associated with OSA32 and can potentially improve
with CPAP therapy. Animal models have shown increases in
serum triglyceride and low-density lipoprotein-cholesterol
levels with exposure to CIH, possibly through the increased
activity of SREBP-1 and SCD-1. This increased activity
enhances conversion of saturated to monounsaturated fatty
acids, increases serum triglycerides, and promotes lipoprotein secretion.79 Another study has shown that lipid profiles
in patients with OSA can improve with CPAP therapy with
improvement seen in serum triglycerides, low-density lipoprotein, nonhigh-density lipoprotein, total cholesterol, and
the high-density lipoprotein to total cholesterol ratio.65
Abdominal and visceral obesity is another important
feature of metabolic syndrome linked with increased cardiovascular risk in patients with OSA. This has been posited to
improve with CPAP therapy. However, randomized controlled
studies of nondiabetic patients with OSA failed to demonstrate a significant impact of CPAP therapy on visceral,
subcutaneous, or hepatic fat distribution.63,64,80
Despite the contradictory and conflicting nature of some
of the data, there is mounting evidence that CPAP therapy
for moderate-to-severe OSA may improve components
of metabolic syndrome, and this may ultimately reduce
the cardiovascular and cerebrovascular risk associated
with OSA.
Treatments other than CPAP are available for OSA. Mandibular advancement oral appliance therapy is an effective
treatment of OSA and has also been shown to improve some
outcomes related to the metabolic syndrome. Oral appliance
therapy for OSA has been shown to improve markers of lipid
peroxidation that are linked to endothelial dysfunction.81
Markers of endothelial dysfunction, an important event that
precedes the development of atherosclerosis and might predict future cardiovascular events, may also improve with oral
appliance therapy for OSA.82 Some studies have also shown
improvement in hypertension with this therapeutic modality
in OSA.83 A parallel group study showed similar reduction in
morning diastolic blood pressure between CPAP and dental
appliance therapy after 10 weeks of use.84
The role of weight loss in improving features of the
metabolic syndrome such as insulin resistance has been
assessed among patients undergoing bariatric surgery.
Weight loss following bariatric surgery has been associated
with improvement in insulin resistance, as well as partial
or complete remission of T2DM in a subset of patients.85
However, an independent impact of improved OSA versus
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weight loss on improvement in manifestations of T2DM has
not been established.

Clinical implications
Screening for OSA in patients with T2DM
With the increasing prevalence of T2DM and obesity in the
aging population, there is a growing need to identify those
patients with T2DM who might also be at risk of OSA,
since both are independent risk factors for cardiovascular
and cerebrovascular disease and are often comorbid chronic
conditions.75 The identification of OSA in patients with
T2DM is therefore of paramount importance, and this task
often falls to the primary care physician.
Assessing risk of OSA might be challenging in primary
care settings because many patients with OSA do not report,
in routine office visits, “typical” OSA-related symptoms, such
as heavy snoring, witnessed pauses of breathing during sleep,
and excessive daytime somnolence. Other risk factors might
be considered, including anatomic features such as obesity
(BMI .30 kg/m2), large neck circumference (.16 in for
females; .17 in for males), a crowded oropharynx with a low
lying soft palate, large base of tongue and tonsillar hypertrophy,
as well as craniofacial abnormalities including retrognathia.86
Evaluation of OSA symptoms should ideally be part of routine
patient history and physical examinations. However, this might
not always be practical or feasible, especially in primary care
settings. Several self-administered screening tools and questionnaires have been developed to facilitate identification of patients
who may require referral or testing for OSA.
The Epworth Sleepiness Scale is one such tool that
measures subjectively reported tendency to fall asleep during a variety of situations. However, it lacks sensitivity for
detection of moderate-to-severe OSA. The STOP-Bang
questionnaire assesses various risk factors for OSA and has
reasonable sensitivity and specificity when a cutoff score of
5–8 is used.87,88 However, this tool was specifically developed
for use in presurgical testing populations. As a result, its
validation may not apply to primary care or other settings.
The Berlin questionnaire is another short, ten-question survey
comprising three different categories. A high risk of OSA is
identified by positive answers in two or more of the categories,
which yields a 78.6% sensitivity with a 50.5% specificity,
for detection of moderate-to-severe OSA.87 The Sleep Apnea
Clinical Score is a longer questionnaire (36 items) that has
been validated for calculation of likelihood ratios for the presence of OSA. A score of $15 yields a likelihood ratio of 4.45
of moderate–to-severe sleep apnea.89 The sensitivities and
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Table 1 Predictive value of screening questionnaires for
moderate-to-severe OSA

Sensitivity (%)
Specificity (%)
Odds ratio
(95% CI)
Area under the
ROC (95% CI)

Epworth
Sleepiness
Scale

STOP-Bang
questionnaire

Berlin
questionnaire

39.0
71.4
1.6

87.0
43.3
5.1

78.6
50.5
3.7

0.53

0.64

0.67

Abbreviations: OSA, obstructive sleep apnea; CI, confidence interval; ROC,
receiver–operating characteristic.

specificities of these tools are listed in Table 1.90 The STOPBang questionnaire and the Berlin questionnaire can each
be completed in ,5 minutes, allowing them to be used as
effective OSA screening tools in a busy clinical setting.
Although the sensitivity of the Epworth Sleepiness Scale for
OSA is relatively low, it can also provide useful data regarding the degree of daytime somnolence and its improvement
with treatment.
Utilization of these tools in primary care offices might
aid in raising the suspicion for OSA in diabetic populations in which the risk is already higher than in the average
population. This can ultimately facilitate referral to sleep
practices where further evaluation for OSA can occur.

Diagnosis of OSA
Once a patient is referred for further sleep evaluation,
the diagnosis of OSA and its severity can be assessed by
recording physiologic parameters during sleep. The gold
standard is attended polysomnography (PSG) performed
in a sleep laboratory. This comprehensively assesses sleep
and breathing with recordings of the electroencephalogram,
electromyogram, electrooculogram, electrocardiogram,
nasal/oral airflow surrogate, thoracic and abdominal respiratory effort, oxygen saturation, and an audio recording of
snoring throughout the night.91 Home sleep testing (HST),
with more limited respiratory assessment, has recently
gained popularity because of its ease of use and reduced
cost when compared to standard PSG. This may be useful
in cases where the pretest probability of moderate or severe
OSA is high.92,93 However, it must be noted that HST has
many important limitations that reduce its utility in certain
settings. It usually only monitors a surrogate for airflow,
respiratory effort, and oxygen saturation and provides no
objective measure of total sleep duration or sleep quality.
This may lead to underestimation of the severity and impact
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of sleep disordered breathing, particularly in those patients
with milder forms of OSA. In addition, automated scoring
of HST may further underestimate the severity of OSA
compared with manual scoring of these studies.94
Patient selection for HST is also important as falsenegative results may occur in patients with coexisting insomnia who might spend a large portion of the test night awake,
since the AHI is calculated in reference to recording time
rather that total sleep time, which is usually not measured.
HSTs are also inadequate for accurate assessment of more
complex sleep disorders, especially in those patients with
significant comorbid cardiopulmonary disease. Therefore,
patients suspected of having OSA on a clinical basis who
then have negative HST results might need referral for confirmatory in-laboratory PSG.93

Treatment of OSA
Various treatment modalities are available for OSA. In order
to maximize the chances of achieving successful therapeutic outcomes, strong consideration must also be given to
patient-specific needs, expectations, and comorbidities such
as cardiac, pulmonary, and cerebrovascular disease, as well
as to coexisting sleep disorders such as insomnia.
CPAP therapy remains the gold standard for the treatment
of OSA, with randomized, placebo-controlled trials clearly
demonstrating significant improvement in quality of life,
daytime somnolence, and neurobehavioral performance.
These improvements have been observed for all degrees of
OSA, including the milder forms.95,96 Several alternatives to
CPAP therapy can also be considered and include oral appliance therapy for mandibular advancement,97,98 surgeries of the
upper airway; maxillofacial surgery for jaw advancement,99
and bariatric surgery for weight loss100 in appropriately
selected patients. As OSA is a chronic condition, long-term
disease management with monitoring of compliance and
treatment efficacy is essential to achieving optimal functional outcomes, as well as for long-term cardiovascular
risk reduction.101

Conclusion
In summary, there is a high prevalence of insulin resistance
and T2DM in patients with OSA. An even higher prevalence
of OSA has been documented in those patients with T2DM
who are obese. The multiple physiologic disturbances in OSA,
including sleep fragmentation, activation of the sympathetic
nervous system, and CIH secondary to recurrent apneas,
may contribute to abnormal glucose and insulin metabolism.
CIH, with its associated systemic inflammation and oxidative
stress, has been demonstrated in animal models to contribute
122
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to hepatic and peripheral insulin resistance as well as to pancreatic β-cell dysfunction, independent of obesity.
Given the links between T2DM and OSA, screening for
OSA in this population is important as effective treatment of
OSA with CPAP may not only improve sleep apnea-related
symptoms and quality of life but also improve components
of the metabolic syndrome that contribute to long-term cardiovascular and cerebrovascular risk.
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